Skip to main content
Transcenta Holding Limited logo

Transcenta Holding Limited — Investor Relations & Filings

Ticker · 6628 ISIN · KYG9005B1041 HKEX Manufacturing
Open in API
Filings indexed 482 across all filing types
Latest filing 2023-04-13 Regulatory Filings
Country HK Hong Kong
Listing HKEX 6628

About Transcenta Holding Limited

http://www.transcenta.com

Transcenta Holding Limited is a clinical-stage global biotherapeutics company specializing in the discovery, research, development, and manufacturing of differentiated antibody-based therapeutics. The company operates a fully integrated platform, utilizing a unique antibody generation platform based on Immune Tolerance Breaking Technology to generate candidate leads. Its robust pipeline includes therapeutic antibody molecules targeting oncology and selected non-oncology indications, such as bone and kidney disorders. The company employs advanced bioprocessing technologies, including perfusion-based continuous bioprocessing, to accelerate process development and reduce manufacturing costs.

Recent filings

Filing Released Lang Actions
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2023
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 January 2023. It details movements in authorized and issued shares, share options, warrants, convertibles, and other share-related transactions. It includes confirmations related to securities issued and compliance with listing rules. The document is a regulatory filing reporting monthly share capital and share movement information to the Hong Kong Exchanges and Clearing Limited. It is not an annual or interim financial report, earnings release, or management discussion. It is not a proxy, voting result, or remuneration report. It is a routine regulatory disclosure of share capital movements and confirmations. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2023-04-13 English
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2022
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 December 2022. It details movements in authorized and issued share capital, share options, repurchases, cancellations, and confirmations related to securities issued by the company. The document is a regulatory return submitted to the Hong Kong Exchanges and Clearing Limited, reporting share capital changes and share transactions for the month. It does not contain financial statements, earnings data, management discussion, or audit information. It is a regulatory filing reporting share capital movements and confirmations, fitting the category of Regulatory Filings (RNS) as it does not match other more specific categories like Share Issue/Capital Change (SHA) because it is a formal monthly return report rather than a single announcement of a share issue or capital change event.
2023-04-13 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2023
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return regarding movements in securities for Transcenta Holding Limited, including authorized share capital, issued shares, share options, and other share-related movements. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The document is a regulatory submission reporting share capital and share issuance activities for the month ended 31 March 2023. It does not contain financial statements, earnings data, or management discussion, nor is it an announcement of a report publication. It is a regulatory filing reporting share capital movements and confirmations related to securities issuance under listing rules. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2023-04-11 English
GRANT OF AWARD SHARES AND OPTIONS PURSUANT TO THE SHARE INCENTIVE SCHEME
Director's Dealing Classification · 95% confidence The document is an announcement from Transcenta Holding Limited regarding the grant of award shares under the company's Share Incentive Scheme. It details the number of shares granted, the recipients (including directors and senior management), vesting periods, performance targets, clawback mechanisms, and compliance with listing rules. The document also mentions an upcoming general meeting to approve part of the grant. There are no financial statements or comprehensive financial data presented, nor is this a full report or earnings release. The content focuses on share awards to directors and senior management, which aligns with disclosures about director dealings or insider share transactions. Therefore, the document fits best under the category of Director's Dealing (DIRS), as it reports personal share transactions by company directors and executives.
2023-04-06 English
GRANT OF AWARD SHARES AND OPTIONS PURSUANT TO THE SHARE INCENTIVE SCHEME
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the grant of award shares and options under a share incentive scheme. It details the number of shares and options granted, vesting periods, performance targets, clawback mechanisms, and related governance matters. It references compliance with Listing Rules and mentions a forthcoming general meeting to approve certain grants. The content focuses on share-based compensation and incentive grants to employees and senior management, including a named executive. There is no financial statement, earnings data, or comprehensive report content. The document is not a full annual or interim report, nor is it a call transcript or audit report. It is not a proxy solicitation or voting results announcement, but rather a regulatory announcement about share awards and options granted. This fits the category of a Regulatory Filing (RNS) as it is a formal announcement required by the stock exchange rules about share incentive grants and related governance disclosures.
2023-03-31 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2022 AND CHANGE IN USE OF PROCEEDS
Annual Report Classification · 95% confidence The document is an announcement titled 'ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2022 AND CHANGE IN USE OF PROCEEDS' from Transcenta Holding Limited. It contains detailed audited consolidated financial results for the full fiscal year ended December 31, 2022, including revenue, income, expenses, and comprehensive loss figures. It also includes extensive business highlights, clinical program achievements, and operational updates. The presence of audited financial statements reviewed by the audit committee and the company's auditor, along with detailed financial and operational data for the full year, indicates this is a full annual financial report rather than a brief earnings release or a report publication announcement. The document length (15,000 characters) and content depth support classification as an Annual Report equivalent. Therefore, the appropriate filing type is Annual Report (10-K). FY 2022
2023-03-30 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.